de Miguel‑Perez, Diego
Ak, Murat
Mamindla, Priyadarshini
Russo, Alessandro
Zenkin, Serafettin
Ak, Nursima
Peddagangireddy, Vishal
Lara‑Mejia, Luis
Gunasekaran, Muthukumar
Cardona, Andres F.
Naing, Aung
Hirsch, Fred R.
Arrieta, Oscar
Colen, Rivka R.
Rolfo, Christian
Article History
Received: 31 January 2024
Accepted: 27 February 2024
First Online: 15 March 2024
Declarations
:
: All patients provided written informed consent and included in the clinical trial NCT02574598. The study was approved by the ethics committee of the institutional review board of the National Cancer Institute, Mexico and performed in accordance with the Declaration of Helsinki and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice.
: No patient personal data is being published and all authors agreed to the content of the paper.
: <b>A. Russo</b> reports advisory board role/consultancy from AstraZeneca, MSD, Novartis, Pfizer, BMS, Roche, and Amgen unrelated to the current work. <b>A. F. Cardona</b> discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox and The Foundation for Clinical and Applied Cancer Research – FICMAC. Advisor role to EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research – FICMAC. <b>A. Naing</b> discloses research funding from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG. Advisory board activity for CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, Kymab, STCube Pharmaceuticals, and Deka Biosciences. He reports advisory board role for Takeda, CSL, Behring, Horizon, and Pharming. Travel and accommodation expense from ARMO BioSciences: Spouse and research funding from Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. <b>F. R. Hirsch</b> reports advisory boards consultancy for Bristol-Myers Squibb, AstraZeneca/Daiichi, Sanofi/Regeneron, Novartis, Amgen, OncoCyte, Genentech, and Nectin Therapeutics. <b>C. Rolfo</b> has received speaker honoraria from AstraZeneca, Roche and MSD, advisory board honoraria from Inivata, Archer, Boston Pharmaceuticals, MD Serono and Novartis, Bayer, Invitae, Regeneron, Janssen, Bostongene, Novocure, Scientific Advisory Board member of Imagene, and institutional research funding from LCRF- Pfizer and NCRF, non-renumerated research support from GuardantHealth and Foundation Medicine. He has non-renumerated leadership roles at the International Society of Liquid Biopsy (ISLB), the International Association for Study of Lung Cancer (IASLC), the European School of Oncology (ESO), and Oncology Latin American Association (OLA). The rest of the authors declares no conflict of interests.